<!doctype html>
<html lang="en">
<head>
<meta charset="utf-8" />
<title>The Science | LiquidMammo™ microRNA Early Detection</title>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link rel="stylesheet" href="assets/css/styles.css" />
</head>
<body>
<header class="container"><nav><a href="index.html">← Home</a></nav></header>
<main class="container">
  <h1>The Science Behind LiquidMammo</h1>
  <h2>microRNA & tumor biology</h2>
  <p>microRNA regulates gene expression central to tumor initiation and progression; shifts in these small RNAs can precede structural imaging changes, making them promising biomarkers for earlier detection.</p>

  <h2>Why complement mammography?</h2>
  <p>
    Mammography reduces mortality at population level, but limitations persist: false‑negatives, especially in dense breasts; frequent false‑positives over time; and modest detection yield per 1,000 screened.
  </p>

  <h2>Clinical reality in dense breasts</h2>
  <p>
    Dense breast tissue can mask tumors (similar x‑ray appearance), and interval cancers are more common; adjunct screening approaches (e.g., molecular or MRI/US in select groups) can improve detection.
  </p>

  <h2>Ongoing validation</h2>
  <p>LiquidMammo’s analytical and clinical validation follows standard LDT practices; performance metrics will be communicated as studies complete. It is not yet FDA‑cleared/approved.</p>
</main>
<footer class="container small">© <script>document.write(new Date().getFullYear())</script> MultiOmics Inc.</footer>
</body>
</html>